Equities research analysts expect CME Group Inc (NASDAQ:CME) to announce sales of $1.20 billion for the current quarter, Zacks Investment Research reports. Four analysts have provided estimates for CME Group’s earnings. The highest sales estimate is $1.22 billion and the lowest is $1.18 billion. CME Group reported sales of $1.24 billion during the same quarter last year, which would suggest a negative year over year growth rate of 3.2%. The business is scheduled to announce its next quarterly earnings report on Thursday, February 13th.

According to Zacks, analysts expect that CME Group will report full year sales of $4.92 billion for the current financial year, with estimates ranging from $4.91 billion to $4.94 billion. For the next fiscal year, analysts forecast that the company will report sales of $5.15 billion, with estimates ranging from $4.98 billion to $5.27 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for CME Group.

CME Group (NASDAQ:CME) last issued its quarterly earnings data on Wednesday, October 30th. The financial services provider reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.75 by $0.15. The firm had revenue of $1.28 billion during the quarter, compared to analysts’ expectations of $1.27 billion. CME Group had a net margin of 40.93% and a return on equity of 9.54%. The business’s revenue was up 41.3% on a year-over-year basis. During the same period last year, the company earned $1.45 earnings per share.

A number of research analysts have recently issued reports on the stock. BidaskClub cut shares of CME Group from a “buy” rating to a “hold” rating in a report on Friday, October 18th. JPMorgan Chase & Co. cut their price target on shares of CME Group from $183.00 to $173.00 and set an “underweight” rating on the stock in a report on Friday, December 6th. Citigroup boosted their price target on shares of CME Group from $220.00 to $240.00 and gave the stock a “buy” rating in a report on Monday, October 21st. Oppenheimer began coverage on shares of CME Group in a report on Monday, September 16th. They set an “outperform” rating and a $234.00 price target on the stock. Finally, ValuEngine cut shares of CME Group from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd. Three equities research analysts have rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the stock. CME Group presently has an average rating of “Hold” and a consensus price target of $207.42.

In other CME Group news, CEO Terrence A. Duffy sold 39,309 shares of CME Group stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $202.38, for a total value of $7,955,355.42. Following the sale, the chief executive officer now owns 46,684 shares of the company’s stock, valued at $9,447,907.92. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Ronald A. Pankau sold 300 shares of CME Group stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $199.02, for a total transaction of $59,706.00. Following the completion of the sale, the director now directly owns 3,906 shares in the company, valued at approximately $777,372.12. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by insiders.

A number of hedge funds have recently made changes to their positions in the business. Nuveen Asset Management LLC raised its position in shares of CME Group by 18,355.3% in the second quarter. Nuveen Asset Management LLC now owns 3,238,530 shares of the financial services provider’s stock valued at $628,631,000 after purchasing an additional 3,220,982 shares during the period. Parnassus Investments CA bought a new stake in shares of CME Group in the second quarter valued at approximately $544,292,000. Magellan Asset Management Ltd bought a new stake in shares of CME Group in the second quarter valued at approximately $418,297,000. Fiera Capital Corp raised its position in shares of CME Group by 17.0% in the second quarter. Fiera Capital Corp now owns 2,960,477 shares of the financial services provider’s stock valued at $574,658,000 after purchasing an additional 429,235 shares during the period. Finally, Amundi Pioneer Asset Management Inc. raised its position in shares of CME Group by 30.4% in the second quarter. Amundi Pioneer Asset Management Inc. now owns 1,664,500 shares of the financial services provider’s stock valued at $323,097,000 after purchasing an additional 388,008 shares during the period. 84.27% of the stock is currently owned by institutional investors and hedge funds.

Shares of NASDAQ CME traded up $1.45 during mid-day trading on Monday, reaching $204.59. 891,892 shares of the company’s stock traded hands, compared to its average volume of 1,174,438. The stock has a market cap of $73.36 billion, a P/E ratio of 30.00, a PEG ratio of 4.04 and a beta of 0.17. The business has a 50-day simple moving average of $203.13 and a 200 day simple moving average of $205.64. CME Group has a 1-year low of $161.05 and a 1-year high of $224.91. The company has a debt-to-equity ratio of 0.14, a current ratio of 1.04 and a quick ratio of 1.04.

The company also recently declared a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Tuesday, December 10th will be issued a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.47%. The ex-dividend date of this dividend is Monday, December 9th. CME Group’s dividend payout ratio (DPR) is presently 43.99%.

CME Group Company Profile

CME Group Inc, through its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products across various asset classes, including futures and options based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals, as well as fixed income products.

Further Reading: Percentage Decliners

Get a free copy of the Zacks research report on CME Group (CME)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for CME Group (NASDAQ:CME)

Receive News & Ratings for CME Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CME Group and related companies with MarketBeat.com's FREE daily email newsletter.